Bristol-Myers Squibb Company (BMY) research: valuation against peers, fundamentals over time, risk and news coverage
ChartVs peersValuationValue mapQuartersScaleMarginsTrajectoryCash qualityPer shareReinvestmentBalance sheetStreetRiskSeasonalityOur coverage
BMY
Bristol-Myers Squibb CompanyUSD
59.59
+1.33% today
Market cap
—
P/E trailing
—
P/E forward
—
EV/EBITDA
—
Op margin
—
Rev growth
—
Div yield
—
Beta
—
Price navigator — BMY
No data in this window.
INDY NEWS coverage of BMY1
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYNEUTRALL3Harris Hands Leadership to Insider Sam Mehta as Kubasik Exits
L3Harris named insider Sam Mehta chief executive as Christopher Kubasik steps down, an orderly succession that points to strategic continuity at the defense contractor. The move lands alongside a broader wave of executive reshuffling across financials and healthcare, including Citigroup's appointment of Adam Clark as wealth planning head.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.
Guidance reliability · BMYmethodology·all companies
Only 4 resolved forecasts on record — below the 6-period threshold, so no verdict is published.
n = 4 resolved forecasts · FY 2022 to FY 2024 · 7 still outstanding
Insufficient sample — no verdict published. BMY has 4 resolved forecasts on record, below the 6 needed before we will characterise a management team’s forecasting. The record below is published in full; the company is excluded from every ranking on this site until it clears the threshold.
Pattern
Not enough resolved periods
4 resolved
Avg. signed deviation
−22.9%
outside its own range
Avg. vs midpoint
−24.7%
where in the range it lands
Avg. range width
5.0%
room it leaves itself
In line1Below guidance3
Next report expected 29 Oct 2026 (Q3 FY2026) — Estimated from the issuer's own filing history: FY2025Q3 results were released on 2025-10-30. source
The record — 24 forecasts, 11 scoredevery figure sourced
| Period | Measure | Guided | Issued | Reported | Landed | Deviation | Verdict | Sources |
|---|---|---|---|---|---|---|---|---|
| FY 2026revised | EPS (adj.) | $6.75–$7.00 | 2026-07-30 | — | — | — | PENDING | guidance |
| “As a result of these guidance updates, non-GAAP EPS is increasing to an anticipated range of $6.75 - $7.00.” | ||||||||
| FY 2026 | Revenue (adj.) | $49.00–$50.00bn | 2026-07-30 | — | — | — | PENDING | guidance |
| “Bristol Myers Squibb is increasing its full-year, non-GAAP revenue guidance from a range of approximately $46.0 billion to $47.5 billion to a range of approximately $49.0 billion to $50.0 billion.” | ||||||||
| FY 2026revised | EPS (adj.) | $6.05–$6.35 | 2026-04-30 | — | — | — | PENDING | guidance |
| “Reaffirms 2026 financial guidance with revenues of ~$46.0 billion to $47.5 billion; Non-GAAP EPS range of $6.05 to $6.35, with total revenues and non-GAAP EPS trending toward the upper end of the ranges” | ||||||||
| FY 2026revised | Revenue | $46.00–$47.50bn | 2026-04-30 | — | — | — | PENDING | guidance |
| “Reaffirms 2026 financial guidance with revenues of ~$46.0 billion to $47.5 billion; Non-GAAP EPS range of $6.05 to $6.35, with total revenues and non-GAAP EPS trending toward the upper end of the ranges” | ||||||||
| FY 2026 | EPS (adj.) | $6.05–$6.35 | 2026-02-05 | — | — | — | PENDING | guidance |
| “Provides 2026 guidance with revenues of ~$46.0 billion to $47.5 billion; Non-GAAP EPS range of $6.05 to $6.35” | ||||||||
| FY 2026 | Revenue | $46.00–$47.50bn | 2026-02-05 | — | — | — | PENDING | guidance |
| “The company estimates total revenues will be approximately $46.0 billion to $47.5 billion.” | ||||||||
| FY 2025revised | EPS (adj.) | $6.40–$6.60 | 2025-10-30 | — | — | — | PENDING | guidance |
| “Non-GAAP EPS is now expected to be in the range of $6.40 - $6.60, inclusive of an $(0.80) per share net impact related to Acquired IPRD charges and licensing income.” | ||||||||
| FY 2025revised | Revenue (adj.) | $47.50–$48.00bn | 2025-10-30 | — | — | — | PENDING | guidance |
| “Bristol Myers Squibb is increasing its full-year 2025 non-GAAP revenue guidance from a range of approximately $46.5 billion to $47.5 billion, to a range of approximately $47.5 billion to $48.0 billion.” | ||||||||
| FY 2025revised | EPS (adj.) | $6.35–$6.65 | 2025-07-31 | — | — | — | PENDING | guidance |
| “Non-GAAP EPS is now expected to be in the range of $6.35 - $6.65, inclusive of an unfavorable $(0.57) per share impact from the BioNTech Acquired IPRD charge this quarter.” | ||||||||
| FY 2025 | Revenue (adj.) | $46.50–$47.50bn | 2025-07-31 | — | — | — | PENDING | guidance |
| “Bristol Myers Squibb is increasing its full-year 2025 non-GAAP revenue guidance from a range of approximately $45.8 billion to $46.8 billion, to a range of approximately $46.5 billion to $47.5 billion, reflecting the strength of the Growth Portfolio, better-than-expected Legacy Portfolio sales in the second quarter, and a favorable impact of approximately $200 million related to foreign exchange rates.” | ||||||||
| FY 2025revised | EPS (adj.) | $6.70–$7.00 | 2025-04-24 | — | — | — | PENDING | guidance |
| “As a result of these changes, the company is raising the midpoint of its 2025 non-GAAP EPS guidance by $0.15 per share to an expected range of $6.70 to $7.00.” | ||||||||
| FY 2025revised | Revenue | $45.80–$46.80bn | 2025-04-24 | — | — | — | PENDING | guidance |
| “The company is increasing its full-year revenue guidance from approximately $45.5 billion to a range of approximately $45.8 billion to $46.8 billion, reflecting the strong performance of the Growth Portfolio, better-than-expected Legacy Portfolio sales in the first quarter of 2025, and a favorable impact of approximately $500 million related to foreign exchange rates.” | ||||||||
| FY 2025 | EPS (adj.) | $6.55–$6.85 | 2025-02-06 | — | — | — | PENDING | guidance |
| “Provides 2025 Guidance with Revenues of ~$45.5 Billion; Non-GAAP EPS Range of $6.55 to $6.85” | ||||||||
| FY 2025 | Revenue | $45.5bn | 2025-02-06 | — | — | — | PENDING | guidance |
| “We estimate total revenues to be approximately $45.5 billion, reflecting, as previously expected, the near-term impact of generics across Revlimid, Pomalyst, Sprycel and Abraxane, which we expect to result in a revenue decline of approximately 18-20% of the Legacy Portfolio.” | ||||||||
| FY 2024revised | EPS (adj.) | $0.75–$0.95 | 2024-10-31 | $1.15 | +23.5% | ABOVE | guidance · result | |
| “Raising 2024 Revenue Guidance to Approximately +5% (+6% Adjusting for Foreign Exchange), Non-GAAP EPS Range Increased to $0.75 to $0.95” | ||||||||
| FY 2024 | EPS (adj.) | $7.10–$7.40 | 2024-02-02 | $1.15 | −82.1% | BELOW | guidance · result | |
| “Bristol Myers Squibb provides its 2024 non-GAAP EPS guidance range of $7.10 - $7.40.” | ||||||||
| FY 2023revised | EPS (adj.) | $7.50–$7.65 | 2023-10-26 | $7.51 | 0.0% | IN LINE | guidance · result | |
| “Adjusting GAAP diluted EPS range to $3.68-$3.83 and raising midpoint of Non-GAAP diluted EPS range, with the new range being $7.50-$7.65.” | ||||||||
| FY 2023revised | EPS | $3.68–$3.83 | 2023-10-26 | $3.86 | +0.8% | ABOVE | guidance · result | |
| “Adjusting GAAP diluted EPS range to $3.68-$3.83 and raising midpoint of Non-GAAP diluted EPS range, with the new range being $7.50-$7.65.” | ||||||||
| FY 2023revised | EPS (adj.) | $7.35–$7.65 | 2023-07-27 | $7.51 | 0.0% | IN LINE | guidance · result | |
| “Revises Outlook for Total Revenues to Low Single-Digit Decline, GAAP EPS to $3.72-$4.02, and Non-GAAP EPS to $7.35-$7.65 Due to Lower Expected Revenues for Revlimid and Pomalyst” | ||||||||
| FY 2023revised | EPS | $3.72–$4.02 | 2023-07-27 | $3.86 | 0.0% | IN LINE | guidance · result | |
| “Revises Outlook for Total Revenues to Low Single-Digit Decline, GAAP EPS to $3.72-$4.02, and Non-GAAP EPS to $7.35-$7.65 Due to Lower Expected Revenues for Revlimid and Pomalyst” | ||||||||
| FY 2023 | EPS (adj.) | $7.95–$8.25 | 2023-02-02 | $7.51 | −5.4% | BELOW | guidance · result | |
| “Bristol Myers Squibb provides its 2023 GAAP EPS guidance range of $4.03 - $4.33 and its non-GAAP EPS guidance range of $7.95 - $8.25.” | ||||||||
| FY 2023 | EPS | $4.03–$4.33 | 2023-02-02 | $3.86 | −4.1% | BELOW | guidance · result | |
| “Bristol Myers Squibb provides its 2023 GAAP EPS guidance range of $4.03 - $4.33 and its non-GAAP EPS guidance range of $7.95 - $8.25.” | ||||||||
| FY 2022 | Revenue (adj.) | $46.0bn | 2022-10-26 | — | — | — | PENDING | guidance |
| “Total Sales ~$46.0 billion No change ~$46.0 billion No change” | ||||||||
| FY 2022 | Revenue | $46.0bn | 2022-10-26 | $46.2bn | 0.0% | IN LINE | guidance · result | |
| “Total Sales ~$46.0 billion No change ~$46.0 billion No change” | ||||||||
Every figure above is read from the company’s own filings. “Guidance” links to the 8-K exhibit that issued the forecast; “result” links to the exhibit in which the company reported the outcome. Nothing here is an analyst estimate. How this is measured.
Coverage universe: S&P 100. This is a factual record of what a company forecast and what it then reported. It is not investment advice, and it is not a view on the company’s prospects — we publish the measurement and draw no conclusion from it.